

10/525238

DT01 Rec'd PCT/PTC 22 FEB 2005

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2003/009354

International Filing Date : 22 August 2003 (22.08.2003)

Priority Date(s) Claimed : 23 August 2002 (23.08.2002)

Applicant(s) (DO/EO/US) : Marco FRENTSCH ET AL.

Title: METHOD FOR DETECTING AND ISOLATING T LYMPHOCYTES THAT
RECOGNIZE A DEFINED ANTIGEN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

- ☒ Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
- ☐ within three months of the filing date of a national application other than a CPA under § 1.53(d);
 - ☒ within three months of the actual filing date of the national phase of a PCT application; OR
 - ☐ before the mailing of a first substantive office action (including after filing of an RCE).
- ☐ Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
- ☐ a final rejection under 37 C.F.R. 1.113;
 - ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
 - ☐ a notice of allowance under 37 C.F.R. § 1.311; and

10/525238**DT01 Rec'd PCT/PTT 22 FEB 2005**

is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
- ☐ a check covering the fee of _____ under 37 C.F.R. § 1.17(p).
- ☐ Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- ☐ a final action under 37 C.F.R. § 1.113;
- ☐ termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
- ☐ a notice of allowance under 37 C.F.R. § 1.311;

AND is filed on or before payment of the issue fee; AND is accompanied by:

- ☐ the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of _____ under 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

Cited Materials

- ☐ Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. _____, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- ☒ Copies of materials listed but not attached were cited in an international search report dated February 2, 2004.
- ☐ Copies of the materials listed are attached (except for the foregoing).

10/525238
BT01 Rec'd PCT/PTC 22 FEB 2005

Non-English Language References

☒ An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).

☐ A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone
 Y = document of particular relevance when it is combined with another such document
 A = document defining the general state of the art
 O = non-written disclosure
 P = intercalated document
 T = document cited to understand the theory or principle underlying the invention
 E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
 D = cited in the application
 L = cited for another reason
 & = publication of member of same patent family

☐ Translation of other relevant information on foreign search report

Other Information

Payment of Fees Due (If Any):

☐ A check for \$ covering the fee identified above is attached.


☐ Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

10/525238

DT01 Rec'd PCT/FTT 22 FEB 2005

☒ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,


Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: GULDE-0057

Date: February 22, 2005

AJZ:ssr

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet	1	of	2
-------	---	----	---

Application Number	USNP of PCT/EP2003/009354
Filing Date	22 August 2003 (22.08.2003)
First Named Inventor	Marco FRENTSCH ET AL.
Group Art Unit	unknown
Examiner Name	unknown
Attorney Docket Number	GULDE-0057

[illegible][illegible]

09/28/2008

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./

10/525238
 DT01 Rec'd PCT/PT 22 FEB 2005

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	USNP of PCT/EP2003/009354
Filing Date	22 August 2003 (22.08.2003)
First Named Inventor	Marco FRENTSCH ET AL
Group Art Unit	unknown
Examiner Name	unknown
Attorney Docket Number	GULDE-0057

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	003	BERNER B ET AL: "INCREASED EXPRESSION OF CD40 LIGAND (CD154) ON CD4+ T CELLS AS A MARKER OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS" ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 59, 2000, pages 190-195	
	004	SCHOENBECK U ET AL: "CD154 (CD40 LIGAND)" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB, vol. 32, no. 7, July 2000, pages 687-693	
	005	FISHER P J ET AL. "IMMUNOMAGNETIC SEPARATION REAGENTS AS MARKERS IN ELECTRON MICROSCOPY" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 262, no. 1-2, 1 April 2002, pages 95-101	
	006	DATABASE BIOSIS 'ONLINE' BIOSCIENCES INFORAMTION SERVICE, PHILADELPHIA, PA, US; 20 March 2002, LEE BYUNG O ET AL.: "THE BIOLOGICAL OUTCOME OF CD40 SIGNALING IN B LYMPHOCYTES IS DEPENDENT ON THE DURATION OF CD154 EXPRESSION ON T CELLS: RECIPROCAL REGULATION BY IL-4 AND IL-12."	
	007	FASEB JOURNAL, vol. 16, no. 4, 20 March 2002, page A350, ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY; NEW ORLEANS, LOUISIANA, USA; APRIL 20-24, March 20, 2002	
	008	VALMORI D ET AL: "ANTIGEN-TARGETED APPROACH TO ADOPTIVE TRANSFER THERAPY OF CANCER" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 59, no. 9, 1999, pages 2167-2173	

Examiner
Signature

/Phillip Gambel/

Date
Considered

09/28/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./